HLA-DRB1 polymorphisms distribution in chronic dysimmune polyneuropathy.
M Gironi1, F R Guerini, E Beghi
1Department of Neurology, Don C. Gnocchi Foundation IRCCS, S. Maria Nascente, University of Milan, and Department of Biomedical Sciences and Technologies, Don Gnocchi Foundation, San Giuseppe Hospital, Via Capecelatro 66, Milan, Italy. mgironi@dongnocchi.it
Neuromuscular Disorders : NMD
|September 16, 2008
Summary
The HLA-DRB1*15 gene variant, linked to multiple sclerosis, was not found to be more common in chronic dysimmune polyneuropathy patients. No significant differences were observed between patient groups or with healthy controls.
Area of Science:
- Neuroimmunology
- Genetics
- Neurology
Background:
- The human leukocyte antigen (HLA) complex plays a crucial role in immune responses and is associated with various autoimmune diseases.
- HLA-DRB1*15 is a well-established genetic risk factor for multiple sclerosis (MS).
- Chronic dysimmune polyneuropathy (CDP) is a group of neurological disorders characterized by immune-mediated damage to peripheral nerves.
Purpose of the Study:
- To investigate the frequency of the HLA-DRB1*15 polymorphism in adult patients with chronic dysimmune polyneuropathy.
- To explore potential associations between HLA-DRB1*15 and clinical or electrophysiological features within the CDP patient cohort.
- To compare HLA-DRB1*15 frequencies between CDP patients and healthy controls.
Main Methods:
- Genotyping for HLA-DRB1*15 was performed on 84 adult patients diagnosed with chronic dysimmune polyneuropathy.
- A control group of 272 healthy individuals was included for comparison.
- Statistical analyses were conducted to compare allele frequencies between cases and controls, and within the patient group based on gender, antibody status (anti-MAG), and electrophysiological findings.
Main Results:
- No statistically significant difference in the frequency of HLA-DRB1*15 was found between patients with chronic dysimmune polyneuropathy and healthy controls.
- Within the CDP patient cohort, HLA-DRB1*15 frequency did not differ significantly based on gender, peripheral nerve antigen antibody seropositivity, or electrophysiological characteristics.
- A non-significant trend towards an increased frequency of HLA-DRB1*11 was observed in patients with anti-MAG (myelin-associated glycoprotein) neuropathy.
Conclusions:
- The study suggests that HLA-DRB1*15 is not a significant genetic risk factor for chronic dysimmune polyneuropathy.
- The findings do not support a role for HLA-DRB1*15 in the pathogenesis or clinical presentation of CDP.
- Further research may be warranted to explore the potential role of other HLA alleles, such as HLA-DRB1*11, in specific subtypes of neuropathy like anti-MAG neuropathy.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...